ImageneBio (IMA) Other financing activities (2020 - 2025)

ImageneBio (IMA) posted Other financing activities of $45000.0 for Q1 2025, up 200.0% sequentially from $15000.0 in Q3 2023.

ImageneBio (IMA) Other financing activities (2020 - 2025) Analysis & Trends

ImageneBio has reported Other financing activities for 5 years, with the latest figure at $45000.0 in Q1 2025.

Quarterly Other financing activities changed N/A year-over-year to $45000.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $61000.0 (changed N/A YoY) and the FY2023 annual result came in at $136000.0, down 87.58% from the prior year.
Other financing activities advanced to $45000.0 in Q1 2025 per IMA's latest filing, from $15000.0 in the prior quarter.
Over five years, Other financing activities peaked at $132.4 million in Q1 2021 and troughed at -$1.1 million in Q2 2021.
A 4-year average of $16.6 million and a median of $34500.0 in 2022 frame the typical range for Other financing activities.
The sharpest annual moves came in 2021 and 2022: Other financing activities soared 630528.57% in 2021, then plunged 99.63% in 2022.
Over 4 years, Other financing activities stood at -$1.1 million in 2021, then jumped by 100.09% to $1000.0 in 2022, then surged by 1400.0% to $15000.0 in 2023, then surged by 200.0% to $45000.0 in 2025.
According to Business Quant data, Other financing activities over the past three periods registered $45000.0, $15000.0, and $1000.0 for Q1 2025, Q3 2023, and Q4 2022 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	ImageneBio	48.60 Mn	-86.75 Mn	-

Download Data